Theranica Brings First-in-Class, Drug-Free Migraine Care to the Forefront at CNS 2025 with Product Theater and New Real-World Evidence

With a dedicated product theater and new real-world evidence posters, Theranica will spotlight how the Nerivio^® REN wearable is reshaping pediatric migraine care—offering families a proven, drug-free alternative to migraine treatment

BRIDGEWATER, N.J. and NETANYA, Israel, Oct. 8, 2025 /PRNewswire/ -- Theranica, a pioneer in drug-free neuromodulation treatments for idiopathic pain conditions, today announced its participation at the 2025 Child Neurology Society (CNS) Annual Meeting, held in Charlotte, N.C. The company will present two new real-world evidence (RWE) posters and host a dedicated product theater session, highlighting the clinical impact of the FDA-cleared Nerivio^® Remote Electrical Neuromodulation (REN) wearable indicated for both acute and preventive treatment of migraine in people aged 8 and older.

The new data add to the growing body of evidence demonstrating the long-term effectiveness and safety of the Nerivio REN wearable as a non-pharmacological option for patients:

• RWE08: Three-year outcomes – In one of the largest prospective real-world studies of migraine to date (55,000 patients), the Nerivio REN wearable showed no tachyphylaxis (treatment fatigue) and consistent efficacy over three years. Patients used the device an average of 8.4 times per month, achieving sustained pain relief (~74%) and functional disability relief (~70%). Outcomes remained stable over time with minimal device-related adverse events, underscoring its durability and long-term safety.
• RWE10: Timing of treatment – Analysis revealed that patients who initiated treatment within one hour of migraine onset were nearly twice as likely to achieve pain relief, pain freedom and freedom from associated symptoms compared to those who delayed treatment (p<0.001). These findings emphasize the clinical importance of timely intervention with the REN wearable.

Alongside the poster presentations, Theranica will host a product theater showcasing the Nerivio REN wearable's unique role in pediatric neurology. Clinicians will gain insights into its use for both acute and preventive treatment in the pediatric population, without the risks associated with drugs, needles or invasive procedures.

"We are excited to engage with the pediatric neurology community at this year's CNS Annual Meeting," said Alit Stark-Inbar, VP of Medical Information and Research at Theranica. "Through our product theater and new real-world evidence presentations, we look forward to highlighting the clinical value of the Nerivio^® REN wearable as a safe, drug-free migraine treatment option for children and adolescents. Our participation at CNS underscores Theranica's commitment to advancing innovative, family-friendly solutions that meet the unique needs of young patients living with migraine."

The new findings further demonstrate the long-term safety, efficacy and clinical value of the Nerivio REN wearable for people living with migraine. By sharing this evidence with the pediatric neurology community at CNS 2025, Theranica continues to highlight its commitment to expanding access to drug-free, clinically proven interventions that empower patients to better manage migraine symptoms.

For more information, visit Theranica's website.

About Nerivio
The Nerivio^® REN wearable is an acute and preventive (dual-use) prescription migraine treatment that works without drugs, needles, or invasive procedures. FDA-cleared for patients 8 and above, it uses gentle electrical pulses on the arm to activate the brain's natural pain regulation system, relieving migraine symptoms during an attack, and reducing the frequency and burden of future episodes when used preventively. Controlled by a smartphone app, the Nerivio REN wearable offers a safe, effective, and easy-to-use way to manage migraine—without the risk of systemic side effects or drug interactions.

About Theranica
Theranica  is a neuromodulation therapeutics company pioneering drug-free treatments for idiopathic pain conditions. Its FDA-cleared flagship product, Nerivio^®, is the first-and-only prescribed REN wearable for both acute and preventive migraine care.  Used in more than one million treatments across the U.S., Nerivio provides a much-needed option for migraine patient populations with unique qualities, including children, veterans, individuals managing comorbidities, and women of childbearing age. Dedicated to modernizing pain management without drugs or needles, Theranica continues to develop cutting-edge neuromodulation therapies that reshape the way pain is treated.

Theranica Contact:
Ronen Jashek
[email protected]
+972-72-390-9750

Media Contact:
Grey Matter Marketing
[email protected]

SOURCE Theranica